Keywords: s-p, chugai, sign, psoriasis, deal, schering-plough, pharmaceutical
S-P & Chugai Sign Psoriasis Deal
Article | 24 March 1998
Schering-Plough and Chugai Pharmaceutical have signed an agreementgiving S-P exclusive worldwide marketing rights, excluding Japan, to Chugai's maxacalcitol (22-oxacalcitriol), a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
